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Abstract Connective tissue growth factor (CTGF/CCN2)
is a member of the CCN family of matricellular proteins. Its
expression is induced by a number of factors including
TGF-β. It has been associated with fibrosis in various
tissues including the kidney. Diabetic nephropathy (DN)
develops in about 30% of patients with diabetes and is
characterized by thickening of renal basement membranes,
fibrosis in the glomerulus (glomerulosclerosis), tubular
atrophy and interstitial fibrosis, all of which compromise
kidney function. This review examines changes in CTGF
expression in the kidney in DN, the effects they have on
glomerular mesangial and podocyte cells and the tubuloin-
terstitium, and how these contribute to driving fibrotic
changes in the disease. CTGF can bind to several other
growth factors modifying their function. CTGF is also able
to interact with receptors on cells, including integrins,
tyrosine receptor kinase A (TrkA), low density lipoprotein
receptor-related protein (LRP) and heparan sulphate pro-
teoglycans. These interactions, the intracellular signalling
pathways they activate, and the cellular responses evoked
are reviewed. CTGF also induces the expression of
chemokines which themselves have pharmacological
actions on cells. CTGF may prompt some responses by
acting through several different mechanisms, possibly
simultaneously. For example, CTGF is often described as
an effector of TGF-β. It can promote TGF-β signalling by
binding directly to the growth factor, promoting its
interaction with the TGF-β receptor; by triggering intracel-
lular signalling on binding the TrkA receptor, which leads
to the transcriptional repression of Smad7, an inhibitor of
the TGF-β signalling pathway; and by binding to BMP-7
whose own signalling pathway opposing TGF-β is
inhibited, leading to enhanced TGF-β signalling.
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Introduction
Connective Tissue Growth factor (CTGF, CCN2) is a
secreted 36-38 kDa protein and a prototypical member of
the CCN (Cyr61/CTGF/Nov) family of matricellular pro-
teins. Family members have four domains, each of which
can bind several ligands. Amongst these are (a) other
growth factors (e.g. TGF-β, BMP-4 and -7, IGF-1, VEGF),
whose function is then modified; (b) cell surface proteins
(e.g. integrins, LRP-1, heparan sulphate proteogycans,
tyrosine receptor kinase A), through which intracellular
signalling may be initiated; and (c) extracellular matrix
proteins (e.g. fibronectin) which may act as a sink for CCN
proteins and modify their turnover. With so many potential
interactions it is predictable that CCN proteins will
influence many different biological events (Leask and
Abraham 2006). CTGF is typical in this respect. Many
responses triggered by it, or by fragments derived proteo-
lytically from it, have been described since it was
discovered in 1991 (Bradham et al. 1991, de Winter et al.
2008)). However it was recognised early on that CTGF
stimulates the production of extracellular proteins by
mesenchymal cells and that its expression in such cells is
induced by the profibrotic cytokine TGF-β (Frazier et al.
1996), suggesting that it may have an important role in
fibrosis.
About 30-40% of diabetics develop diabetic nephropathy
(DN). In this life threatening disease, the basement
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and of the renal tubules draining the urinary filtrate from
them become thickened. Later the mesangium, an extracel-
lular matrix which supports the glomerular capillary loops,
and the interstitial areas between the tubules become
fibrosed (Mason and Wahab 2003). Expanding mesangial
fibrosis “crushes” the capillaries compromising filtration,
and expanding fibrosis in the interstitium correlates closely
with declining renal function (Steffes et al. 1989, Gilbert
and Cooper 1999). It is widely accepted that these
processes are mediated by TGF-β (Sharma and Ziyadeh
1995, Border et al. 1996) whose expression is elevated in
renal tissues in DN (Yamamoto et al. 1996). Treatment of
diabetic mice (db/db) with a neutralising antibody to TGF-
β1 attenuated glomerular hypertrophy and prevented
increased expression of collagen and fibronectin and
glomerular mesangial matrix expansion (Ziyadeh et al.
2000). However CTGF has many of the same profibrotic
actions as TGF-β and may act as a mediator of TGF-β
actions on mesenchymal cells (Grotendorst 1997). Indeed,
treatment with a CTGF- antisense oligonucleotide attenu-
ates progression of diabetic nephropathy in diabetic mice
(Guha et al. 2007). Moreover high plasma CTGF levels are
an independent predictor of end-stage renal disease and
mortality in DN in human Type 1 diabetes (Nguyen et al.
2008a). Several publications have proposed that CTGF
could be an alternative therapeutic target to TGF-β in DN
(e.g. Crean et al. 2001, Wahab et al. 2001, Blom et al. 2002,
Twigg and Cooper 2004).
Renal CTGF expression in diabetic nephropathy
Each glomerulus comprises a series of capillary loops,
through which blood circulates, and is enclosed by a
Bowman’s capsule. Its supporting core structure, the
mesangium, is composed of mesangial cells surrounded
by their extracellular matrix. The capillary lumens are lined
with fenestrated endothelial cells sitting on a basement
membrane – the glomerular basement membrane (gbm).
Water and small solutes in the blood diffuse across the gbm
into the urinary space on the abluminal side, forming the
urinary filtrate. This side of the gbm is covered by the foot
processes of podocytes, also termed glomerular visceral
epithelial cells. The filtrate then passes into the tubular
system where molecules are both absorbed from and added
to the tubular fluid by the lining epithelial cells, finally
forming the urine. The tubules occupy both outer cortical
and inner medullary areas of the kidney and are juxtaposed
to intertubular blood vessels and a small amount of
interstitium which contains a few fibroblast-like cells. This
tubulointerstitium accounts for approximately 90% of
kidney volume (Border et al. 1996).
Only low levels of glomerular CTGF are found in
normal human glomeruli, but both mRNA and protein
levels of the factor increase during the early (incipient)
stage of DN and continue to do so as the disease
progresses. Both glomerular podocytes and mesangial cells
express CTGF in DN (Adler et al. 2001, Wahab et al.
2005a). Similarly, glomerular CTGF mRNA and protein
levelsincreaseinmurinemodelsofDN,initiallyinpodocytes
and later in parietal epithelia (lining the Bowman’s capsule)
and mesangial cells (Roestenberg at al. 2006). Distal to the
glomerulus, CTGF protein levels are increased in proximal
tubular epithelial cells (PTECs) in rodent models of DN in
both type 1diabetes (STZ-rats after 30 weeks) and type 2
diabetes (db/db mouse) (Wang et al. 2001, Guha et al.
2007). Interestingly, CTGF mRNA expression was induced
in mouse PTEC cultures by proximal tubular fluid collected
by micropuncture from STZ-diabetic rats (Wang et al.
2001). PTEC’s would be exposed to low molecular weight
growth factors in the tubular fluid in vivo, such as TGF-β
originating in the glomerular ultrafiltrate. CTGF protein was
also detected in distal tubules of diabetic rats but controls
also stained positively (Wang et al. 2001) so it is not clear
whether its level are increased in the disease state. Although
it is well established that declining renal function during
progressive human DN correlates with interstitial expansion
and fibrosis (reviewed by Gilbert and Cooper 1999), few
studies have specifically addressed the expression of CTGF
in interstitial cells in DN. One reason for this may be
because rodent models of DN show little or no interstitial
fibrosis even though glomerular changes are well developed.
However STZ-diabetic mice show some increase in CTGF
mRNA in tubulointerstitial areas and in vessel walls
(Roestenberg et al. 2006) and CTGF mRNA expression is
elevated in human renal interstitial fibrosis in a variety of
kidney diseases, including DN. The interstitial cells over-
expressing CTGF were indentified as myofibroblasts by
their co-expression of α-smooth muscle actin (Ito et al.
1998).
Increased CTGF expression in renal cells in DN is likely
to be induced by several different factors, including the
high glucose environment, mechanical strain, TGF-β,
Advanced Glycation End Product (AGE) – proteins and
reactive oxygen species (ROS) ((Murphy et al. 1999, Riser
et al. 2000, Wahab et al. 2001, Mason and Wahab 2003,
Burns et al. 2006). AGE-proteins and ROS form in tissues
in high glucose conditions and mesangial cells are subject
to mechanical strain due to elevated systemic and intra-
glomerular pressure in diabetes (Forbes et al. 2007). CTGF
is also able to auto-induce further CTGF gene expression in
mesangial cells (Riser et al. 2000). It should be noted that
one group reported a decrease in glomerular CTGF mRNA
in DN in type 2 diabetes. This correlated with a decrease in
a podocyte specific marker and mRNAs indicating podo-
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expression, overall glomerular levels of CTGF mRNA may
decrease with increasing podocyte loss.
CTGF and mesangial cells
CTGF induces many responses in human mesangial cells in
vitro which are relevant to the development of glomerul-
opathy in DN in vivo. It stimulates fibronectin and
plasminogen activator inhibitor-1 synthesis, thus contribut-
ing to the mesangial extracellular matrix and, potentially,
opposing turnover of the matrix since plasminogen activa-
tor is an important activator of matrix metalloproteinases
(Wahab et al. 2001). CTGF also upregulates expression of
α5β1 integrin, a plasma membrane anchor to which
fibronectin must attach to permit the formation of an
extracellular fibronectin fibrillar network. Increased levels
of ligand-occupied β1 integrin appear on the cell surface in
cells treated with CTGF for 48 h, promoting both increased
cell adhesion and mesangial matrix expansion (Weston
et al. 2003). However over short periods (12 h) CTGF
induced dissolution of mesangial cell focal adhesions and a
transient disassembly of the actin cytoskeleton, which
reformed after 24 h. In vitro, these cytoskeletal changes
may facilitate increased mesangial cell migration which was
maximal after 4 h of CTGF treatment (Crean et al. 2002).
Interestingly mesangial cell migration in response to CTGF
was abrogated in a high glucose (30 mM) environment.
Migration requires activation of PKCζ and CTGF was
unable to stimulate further increases in phosphorylation of
PKCζ which was already highly phosphorylated after
exposure to high glucose. Other CTGF responses remained
intact in high glucose (Furlong et al. 2007). These results
illustrate that some CTGF-induced cell responses are likely
to be time and context dependent.
CTGF induces mesangial cell cycle arrest in late G1
phase. This occurs by induction of Cyclin D1, which
initiates the G1 phase, and by stimulating the expression of
the cyclin-dependent kinase inhibitors p15
INK4, p21
Cip1
and p27
Kip1 which bring about arrest in late G1. This arrest
is accompanied by mesangial cell hypertrophy as the cells
continue to synthesize proteins at a high level (Wahab et al.
2002). Furthermore, CTGF blocks mesangial cell death by
inducing MAP kinase phosphatase-1(MKP-1), which pre-
vents MAPK p38 phosphorylation and apoptosis (Wahab
et al. 2007). Persistence of myofibroblast-like cells produc-
ing high levels of extracellular matrix proteins is one of the
hallmarks of fibrosis, in contrast to apotosis of such cells in
damaged tissue undergoing normal wound healing and
repair. TGF-β also induces these changes in mesangial
cells. However such TGF-β-induced effects are blocked by
treating the cells with a CTGF-antisense oligonucleotide, or
CTGF-siRNA. Since mesangial matrix expansion, mesan-
gial cell hypertrophy, and prolonged cell survival, all occur
in the mesangium in DN, it is likely that TGF-β plays a key
role in orchestrating these events in the disease, but that
CTGF facilitates its actions (Wahab et al. 2007), as
discussed below.
CTGF and podocytes
The earliest sign of onset of DN is microalbuminuria.
Glomerular permeability to plasma proteins increases
progressively as the disease advances and persistent
proteinuria may contribute to tubular damage further along
the nephron (Strutz 2008). The change in permeability is
due predominantly to podocyte injury and loss, and to
changes in the slit diaphragms, regions of special protein
composition between adjacent gbm attachment sites of
podocyte foot processes (Wolf et al. 2005, Li et al. 2007).
Recent studies of STZ-induced diabetes in mice which are
transgenic for specific expression of CTGF in podocytes
point to an important role for CTGF in microalbuminuria.
After 12 weeks of diabetes CTGF protein levels were
higher in podocytes of transgenic mice than in non-
transgenic mice and urinary albumin excretion was en-
hanced significantly in the former compared to the latter.
The increased albuminuria may relate to podocyte injury in
the diabetic transgenics since their podocytes were vacuo-
lated, reduced in number, and levels of podocin, a protein
known to be critical for slit diaphragm function, were partly
reduced (Yokoi et al. 2008). The biochemical mechanism
underlying the link between podocyte CTGF expression
and microalbuminuria is currently unknown. However it is
noteworthy that whilst treatment of diabetic mice (db/db)
with an anti-TGF-β antibody prevented increased kidney
matrix protein expression and mesangial expansion, it did
not reduce albuminuria (Ziyadeh et al. 2000), raising the
possibility that CTGF may have a TGF-β-independent role
in the latter. In agreement with this notion, CTGF antisense
oligonucleotide treatment of db/db mice or STZ-induced
diabetic mice did attenuate albuminuria (Guha et al. 2007).
Podocyte-specific CTGF-transgenic mice have two other
interesting characteristics. First, endogenous glomerular
CTGF mRNA levels are also enhanced in diabetic
transgenic mice, but mainly in the mesangial area, suggest-
ing induction of mesangial cell CTGF expression by
transgenic–CTGF from podocytes. Thus CTGF expressed
by one cell type may have paracrine effects on CTGF
expression in another cell type. It was proposed that the
enhanced mesangial expansion seen in these diabetic
transgenics may be due to decreased glomerular MMP2
expression/activity and therefore decreased matrix degrada-
tion, rather than to enhanced matrix synthesis (Yokoi et al.
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renal histology even though their glomerular CTGF protein
levels were five times higher than in non-transgenic mice.
Thus either CTGF levels can vary widely without affecting
tissues or, more likely, CTGF acts on some cells in concert
with one or more other factors, for example TGF-β, and has
no effect if such factors are absent.
CTGF and the tubulointerstitium
Tubular basement membrane thickening, like gbm thicken-
ing (Osterby 1972), occurs early in type1 diabetes. At a
later stage tubular atrophy and loss may occur and the
interstitium becomes fibrotic and greatly expanded (Fioretto
and Maur 2007). This is due to excessive deposition of
extracellular matrix by myofibroblastic type cells, probably
accompanied by decreased matrix degradation. The under-
lying mechanisms of renal interstitial fibrosis have similar-
ities in the different kidney diseases in which it develops
(Nangaku 2004).
Tubular epithelial cells synthesize the matrix proteins of
the tubular basement membrane. Proximal tubular epithelial
cells not only express CTGF in DN but are also likely to be
exposed to CTGF from the glomerulus. Small proteins like
CTGF may filter across the gbm and be present in the
tubular fluid in pharmacologically active concentrations (see
Wang et al. 2001 for example). Mouse PTEC cultures treated
with rCTGF increased expression of fibronectin mRNA, but
not that of Collagen IIIα1 or collagen1α2 chains (Wang
et al. 2001). This may be relevant to the mechanism of
basement membrane thickening since fibronectin is a tbm
component (Brees et al. 1995) whilst the collagens are
components of the interstitial matrix. CTGF may also play a
role in early gbm thickening in DN (Thompson et al. 2007).
Potentially, CTGF secreted by PTECs has important
paracrine actions on renal interstitial fibroblasts in DN.
rCTGF synergised with IGF-1 action on normal renal
fibroblasts (NRK-49F cells), stimulating upregulation of
collagen IIIα1 mRNA. IGF-1 alone had only a modest
stimulatory action whilst CTGF alone had no effect (Wang
et al. 2001). CTGF module 1 has a binding site for IGF-1
which is likely to be important in this synergistic action.
Moreover Lam et al. (2003) showed that human renal
interstitial fibroblasts synthesize both IGF-1 and CTGF and
that their expression increased in hyperglycaemic condi-
tions. This study also recorded that CTGF alone had no
effect on collagen types I and III secretion by these cells but
it enhanced that induced by IGF-1. It was also reported that
an anti-CTGF neutralizing antibody reduced high glucose-
induced secretion of types I and III collagen by the
fibroblasts, indicating the importance of CTGF in intersti-
tial matrix production by these cells in diabetic conditions.
It seems probable that CTGF secreted into the interstitium
by PTECs would contribute to this effect on fibroblasts.
Co-culture experiments of murine interstitial fibroblast
monolayers with murine PTECs grown on cell culture
inserts were used to directly test the paracrine effect of the
latter. The inserts allow diffusion of PTEC-secreted
products into the fibroblast culture. When fibroblasts alone
were stimulated with low doses of TGF-β there was a
modest increase in mRNA levels of proteins involved in
fibrosis, namely collagen I α1, fibronectin (EIIIA form),
PAI-1 and TIMP-1. However in the presence of both TGF-
β and PTECs these fibroblast mRNA levels were greatly
enhanced. The enhancement was blocked in the presence of
a neutralizing anti-CTGF antibody (Okada et al. 2005).
Since rCTGF stimulated increases in the same mRNA’si n
the fibroblast cultures, the enhanced mRNA levels in the
co-culture experiments could be due to either an additive
effect from the PTEC CTGF, or to this CTGF promoting
the effects of TGF-β (see below), or to both actions.
Irrespective of this, the results demonstrate a paracrine
action of epithelial cell CTGF on interstitial fibroblasts.
The origin of the myofibroblasts which lay down
excessive extracellular matrix in interstitial fibrosis in DN
and other renal diseases is not well understood. Some may
derive from the small number of endogenous interstitial
fibroblasts in normal kidneys which become activated by
exogenous factors such as TGF-β, CTGF, and FGF-2,
secreted by infiltrating inflammatory cells in disease (Strutz
2008). Normal rat kidney fibroblasts (NRK clone 49F)
proliferate and differentiate to myofibroblasts (α-SMA
positive and incorporate 3H-proline into collagen) in
response to CTGF. The proliferative activity resides in the
C-terminal domain of CTGF whilst the myofibroblast
differentiation activity is in the N-terminal domain
(Grotendorst and Duncan 2005). Interestingly another
group reported that TGF-β induced proliferation and
differentiation of NRK-49F cells to myofibroblasts and that
this effect was greatly enhanced if CTGF was present. In
these experiments CTGF alone had no effect (Yang et al.
2004). However Gao et al. (2008) reported that primary
cultures of rat renal cortical fibroblasts also proliferate and
up-regulate their collagen and fibronectin expression in
response to CTGF alone.
Renal interstitial myofibroblasts may also arise from
other cell types such as tubular epithelial cells, bone
marrow stem cells, vascular pericytes and endothelial cells.
In one study unilateral ureteric obstruction (UUO) was used
to induce rapid renal interstitial fibrosis in transgenic
reporter mice and bone marrow chimeras. 10 days after
UUO 36% of interstitial fibroblasts (identified by FSP1
expression) were estimated to arise from tubular epithelial
cells (tagged with lacZ expression) and15% from bone
marrow cells (tagged with GFP expression), the latter being
98 R.M. Masononly 3% more than proportionately found in the contralat-
eral unobstructed kidney (Iwano et al. 2002). Both AGE-
albumin and TGF-β induced CTGF expression and EMT in
a renal epithelial cell line (NRK-52E) in vitro. Partial knock
down of CTGF with siRNA attenuated the induction of
EMT by AGE or TGF-β in these cells (Burns et al. 2006).
In contrast to EMT, a recent report focuses attention on
vascular pericytes as a major source of myofibroblasts in
the UUO model. Myofibroblasts were indentified by
coll1a1-GFP expression (Lin et al. 2008). Interestingly
AGE-protein induces CTGF (CCN2) and Cyr 61 (CCN1)
expression in retinal pericytes and adenoviral mediated
over-expression of both proteins in these cells induced de-
adhesion, an event that was followed by apoptosis (Liu
et al. 2008).The effect of CTGF on interstitial blood vessel
pericytes is not known currently. However the larger
interstitial blood vessels remain in human DN and could
provide a source of pericytes, even though the number of
small peritubular vessels is reduced (Lindenmeyer et al.
2007). A further recent study indicates that endothelial to
mesenchymal transition (EndMT) may also contribute
interstitial myofibroblasts in interstitial fibrosis. UUO was
performed in Tie2-Cre;R26R-stop-EYFP mice in which
cells of endothelial lineage are labelled with YFP. Substan-
tial numbers of interstitial cells which were FSP1
+ or α-
SMA
+ also co-expressed YFP(Zeisberg et al. 2008).
Similarly 30-50% of cells which stained positive for these
mesenchymal cell markers in either murine DN (STZ-
induced in CD1 mice), or in Col4a3 knockout mice which
develop interstitial fibrosis, also co-expressed the endothe-
lial marker CD31 (Zeisberg et al. 2008). Whilst concerns
remain that rodent models of interstitial fibrosis may not
precisely mirror that in humans, overall these experiments
point to remarkable plasticity of several cell types in the
tubulointerstitium in renal disease. The exact role of CTGF
in the transition of these various cell types to myofibro-
blasts remains poorly defined. Nevertheless it is noteworthy
that CTGF-antisense oligonucleotide treatment dramatically
attenuated the development of myofibroblasts and renal
interstitial fibrosis in both the rat UUO model (Yokoi et al
2004).and in the remnant kidney following 5/6 nephrecto-
my in TGF-β transgenic mice (Okada et al 2005),
indicating a key function for the factor in the pathogenic
mechanism.
How does CTGF work?
It seems likely that CTGF exerts its effects on cells in
several ways including (i) interaction via one of its domains
with other bioactive proteins, modifying the latter’s action,
(ii) interaction with one or more cell surface tyrosine kinase
receptors, triggering intracellular signalling and down-
stream actions, (iii) interaction with cell surface integrins
triggering intracellular signalling and downstream actions,
(iv) inducing expression of other secreted molecules with
biological actions such as chemokines. There is currently
little information about whether one, or another, of these
actions is relatively more important than others in DN, or in
other disease or biological processes and more than one
route of action may be operative in any particular response
to CTGF. For example, CTGF promotes many profibrotic
effects of TGF-β. It seems to do this by enhancing TGF-β-
Smad2/3 signalling by several mechanisms. One mecha-
nism may involve CTGF binding directly to TGF-β,
facilitating the latter’s interaction with its receptors (Abreu
et al 2002). Another mechanism, operative in mesangial
cells, is by CTGF binding to the tyrosine receptor kinase
complex TrkA/p75
NTR. This triggers intracellular signal-
ling which results in the expression of TIEG-1(TGF-β
immediate early gene-1), a known repressor of Smad7
transcription. The latter is a negative regulator of TGF-β
signalling (Wahab et al 2005b, c). Thus this results in
enhanced transcription of TGF-β responsive genes includ-
ing those encoding extracellular matrix proteins, which
could be important in mesangial expansion in DN. A third
potential mechanism involves BMP-7, a factor which
counteracts TGF-β – mediated fibrosis (Patel and Dressler
2005). Nguyen et al (2008b) showed that CTGF binds to
BMP-7 with high affinity. Moreover renal cortical levels of
CTGF were much higher in STZ-induced DN in CTGF
+/+
mice than in CTGF
+/- mice and DN changes were
attenuated in the latter (Nguyen et al 2008b). Higher levels
of CTGF were shown to inhibit BMP-7 signalling activity
through the Smad1/5 pathway. Normally Smad5 signalling
up-regulates Smad6, which in turn blocks phospho-Smad2/
3 translocation to the nucleus, reducing TGF-β signalling
(Patel and Dressler 2005). Thus with higher CTGF levels
this would not occur, promoting TGF-β –phospho-smad2/3
signalling.
CTGF binds other growth factors including BMP-4,
whose actions it antagonises by preventing BMP-4 -
receptor interaction (Abreu et al 2002). Effects of another
interaction, that between CTGF and IGF-1, were discussed
above. CTGF also binds VEGF165, one of the commonly
expressed splice variants of VEGF-A, interrupting its
interaction with its receptor VEGFR2 and inhibiting
angiogenesis (Inoki et al 2002). VEGF-A is expressed in
podocytes and has autocrine actions on them. Its expression
is increased in both STZ-diabetic rats and db/db mice and
this promotes increased glomerular permeability since
proteinuria was reduced by 50% or more by treatment with
neutralizing anti-VEGF antibodies (reviewed by Wolf et al
2005). Interactions might conceivably occur between
podocyte-derived CTGF and VEGF in early DN, perhaps
opposing VEGF-driven increases in glomerular protein
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protects podocytes from apoptosis (Guan at al 2006) so the
balance between podocyte derived VEGF-A and CTGF
levels and the degree of interaction between the two factors
is, potentially, also important in determining podocyte
survival in DN. In contrast to rodent studies, glomerular
levels of both VEGF-A and CTGF decreased in human DN
which was attributed to podocyte loss (Baelde et al 2008).
These results may reflect the much later time in the human
disease when measurements were made.
CTGF and other members of the CCN family bind to a
variety of integrins expressed by different cells, for example
integrin αvβ3 on endothelial cells (Babic et al 1999),
αIIbβ3 on activated platelets (Jedsadayanmata et al 1999),
α6β1 on skin fibroblasts (Chen et al 2001), αvβ3o n
hepatic stellate cells (Gao and Brigstock 2004), α5β1o n
pancreatic stellate cells (Gao and Brigstock 2006) and
α6β1 on gingival fibroblasts (Heng et al 2006). In doing so
they activate focal adhesion kinase (FAK) and other
intracellular signalling molecules (Chen et al 2001) and
initiate a variety of biological responses, including cell
adhesion, migration, changes in filopodia and lamellipodia,
and extracellular matrix protein deposition. Frequently such
responses depend on simultaneous binding of a heparan
suphate proteoglycan co-receptor. CTGF signalling via
integrin receptors clearly has a role in mesangial cells
which may be relevant to the changes in DN. Crean et al
(2002) reported that CTGF increased fibronectin expression
in human mesangial cells in a β3 integrin-dependent manner
which, via Src activation, stimulates p42/p44MAPK and
PI3K activation. Neutralizing antibody to β3-integrin, or
specific inhibition of MAPK, or of PI3K, all reduced the
CTGF-induced fibronectin synthesis. Thus both the MAPK
and the PI3K/PKB signalling pathways are required to
mediate this effect of CTGF.
CTGF also induced a loss of focal adhesions in
mesangial cells, but independently of β3 integrin -MAPK/
PI3K signalling (Crean et al 2002). Dissolution of focal
adhesions is a prerequisite of actin cytoskeletal reorganisa-
tion for cell migration. CTGF induces cell migration in
vitro by dephosphorylation of focal adhesion kinase and
paxillin, loss of Rho A activity, activation of Cdc 42 and
phosphorylation of PKCζ and GSK-3β (Crean et al 2004).
Mechanisms of mesangial cytoskeletal reorganisation are
pertinent to understanding the pathobiology of DN since F-
actin reorganisation occurs in these cells in a high glucose
environment, mediated by PKCζ, with loss of their
contractile response to vasoconstrictors (Dlugosz et al
2002). Moreover mesangial F-actin fibres undergo rear-
rangement in STZ-diabetic rats (Cortes et al 2000). It was
proposed that during dissolution of the focal adhesion
complex, FAK and paxillin dephosphorylation may depend
on the protein tyrosine phosphatase SHP-2 whose activity
was elevated in the CTGF–treated mesangial cells (Crean
et al 2004). The TrkA/p75 neurotrophin receptor is
expressed in mesangial cells and is activated by CTGF
(Wahabetal2005b). Interestingly, when TrkAwas activated
in PC12 pheochromocytoma cells by its established ligand,
NGF, SHP-2 rapidly and transiently associated with it, was
itself activated by phosphorylation, and was then found
associated with multiple phospho-proteins (Goldsmith and
Koizumi 1997). This raises the speculative question as to
whether a TrkA –SHP-2 pathway could also be involved in
mediating CTGF- driven dissolution of focal adhesions in
mesangial cells. Crean et al (2006) went on to show how
CTGF promotes the depolymerization of F-actin in mesan-
gial cells and proposed that following CTGF interaction
with unspecified cell surface receptors, the PI3K-PKB
pathway is activated. Again, CTGF-TrkA interaction could
be involved since it also activates the PI3K-PKB pathway
(Wahab et al 2005b). PKB then phosphorylates p27
Kip1 at
ser10 and thr157. As a result p27
Kip1 translocates from the
nucleus to the cytoplasm where it binds to and inactivates
RhoA, uncoupling it from the LIM kinase/cofilin system
which regulates actin polymerization/depolymerization.
This role of p27
Kip1 is quite separate from its role as a
cyclin-dependant kinase inhibitor referred to above in the
discussion of CTGF-induced mesangial cell hypertrophy.
Tyrosine receptor kinase A (TrkA) and p75
NTR form a
dual receptor which transduces nerve growth factor -
initiated signals in both neuronal and non- neuronal cells.
This receptor is expressed on mesangial cells and, in
response to CTGF, TrkA rapidly autophosphorylates sever-
al tyrosine residues (490,674/675), triggering association
with several effectors and activating several signalling
pathways. TrkA/ p75
NTR interaction with CTGF was
confirmed by cross-linking experiments. Moreover,
K252a, a selective inhibitor of TrkA kinase activity (Tapley
et al 1992), blocked the rapid phosphorylation of p42/ p44
MAPK (ERK1, 2), JNK, MAPK7 (ERK5) and PKB (Akt)
in mesangial cells treated with CTGF, inferring that these
signalling kinases and their associated pathways are
activated through TrkA (Wahab et al 2005b). CTGF exerts
its effects through TrkA-initiated signalling pathways in
several ways, each of which is blocked by K252a. First,
responses such as upregulated expression of the transcrip-
tion factor TIEG-1 are a direct result of this signalling
(Wahab et al 2005b, 2007). Second, CTGF-enhanced
expression of TGF-β responsive genes such as Col III
and PAI1 results from a stimulatory effect on the TGFb-
Smad signalling pathway. Ligation of TrkA by CTGF
initiates MAPK signalling, TIEG-1 expression and tran-
scriptional repression of Smad 7, as discussed above. This
increases the levels of phospho-smad2/3 and their nuclear
translocation, stimulating transcription of genes having
smad binding elements (SBE) in their promoters (Wahab
100 R.M. Masonet al 2005c). Third, CTGF induces expression of pharma-
cologically active proteins in mesangial cells such as MCP-
1, RANTES and fracktalkine, these chemokines having
important roles in leukocyte chemotaxis and trafficking in
inflammation (Wu et al 2008). There are emerging views
that inflammation and chemokines play important roles in
the pathobiology of DN (Mora and Navarro 2006). Thus,
overall, ligation of TrkA by CTGF is likely to be of key
importance in the development of the disease.
The low density lipoprotein receptor-related protein
(LRP)/α2 –macroglobulin receptor (α2MR) was identified
as a CTGF receptor in bone marrow stromal cells (BMS2)
following chromatography of solubilized cell membranes
on a CTGF-Sepharose affinity column (Segarini et al 2001).
The authors confirmed binding of CTGF to this ~620 kDa
member of the LDL receptor family by competition studies
with known ligands, immunoprecipitation of CTGF-LRP
complex with LRP antibodies, and by showing that CTGF
could bind LRP
+/+ and LRP
+/- mouse embryonic fibroblast
cells, but not LRP
-/- cells. However they were unable to
detect phosphorylation of LRP in cells treated with CTGF.
LRP was also confirmed as a receptor for adhesion of
activated hepatic stellate cells to CTGF (Gao and Brigstock
2003). Subsequently Yang et al (2004) reported that CTGF
induced phosphorylation of the cytoplasmic domain of LRP
in a renal fibroblast cell line (NRK-49F). Unlike TGF-β,
CTGF was unable to stimulate differentiation of these cells
to myofibroblasts. However it increased TGF-β-stimulated
differentiation, including the level of α-SMA expression
(see above). Receptor associated protein (RAP), a known
inhibitor of LRP, blocked CTGF-induced phosphorylation
of LRP and reduced the increased α-SMA expression seen
with co-stimulation with TGF-β and CTGF. These experi-
ments suggest a possible role for CTGF binding to the LRP
receptor in interstitial fibrosis in DN. CTGF also binds the
Wnt co-receptor LRP-6 in Xenopus embryos and inhibits
Wnt signalling (Mercurio et al 2004). The significance of
this interaction has not been explored in mammalian renal
cells but it is known that high glucose downregulates Wnt
signalling in mesangial cells and that this is proapoptotic
(Lin et al 2006).
The C-terminal domain (domain 4), and possibly other
domains, of CTGF contain a heparin/heparan sulphate
binding site which enables it to ligate cell surface heparan
sulphate proteoglycans (HSPGs) (Gao and Brigstock 2004).
HSPGs act as co-receptors when CTGF binds to receptors
such as the αVβ3 integrin, expressed by activated hepatic
stellate cells (Gao and Brigstock 2004). This was shown by
prior treatment of cells with heparitinase1, an enzyme
which specifically degrades the heparan sulphate side
chains of HSPG, or by first culturing cells with sodium
chlorate, a treatment which interferes with the sulphation of
the heparan sulphate chains. In either case the cells were
then unable to adhere to CTGF. Binding of CTGF to the
LRP receptor is also heparin-dependent (Gao and Brigstock
2003). Current data indicate no structural changes in
glomerular cell -associated heparan sulphate in DN (Van
den Born et al 2006, Lauer et al 2007) so it seems likely
that CTGF should be able to interact normally with HSPG
co-receptors in DN.
As discussed above CTGF interacts with several differ-
ent classes of receptor including integrins, TrkA, LRP and
HSPGs. One intriguing speculation is that CTGF-TrkA/
p75
NTR signalling may require ligation of other cell surface
proteins following clustering in the plasma membrane. In
an analogous situation, oligodendrocye α6β1integrins
cluster in lipid rafts containing PDGFα -receptor on
binding their ligand, laminin-2. This enables PDGF to
generate a signal within the raft, leading to PI3K/Akt
activitation and cell survival (Baron et al 2003). Moreover,
TrkA translocates to lipid rafts in PC12 cells on binding
NGF, forming receptor-associated signalling complexes
which result in ERK1/2 activation (Limpert et al 2007).
Could it be that CTGF binds to integrins, HSPGs and TrkA/
p75
NTR receptors in mesangial cell membranes, promoting
clustering into lipid rafts to generate intracellular signaling?
Blocking the integrin or HSPG interaction may then
prevent CTGF signalling via the neurotrophin receptor.
Clearly, much further research is needed before we gain a
fuller understanding of how CTGF achieves its effects and
how we might modulate them therapeutically in disease
states such as DN.
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